Baird analyst Brian Skorney reiterated a 'Buy' rating on Biohaven Ltd. (BHVN) but adjusted the price target downwards from $52 to $48. This revision follows recent regulatory developments concerning the company's drug pipeline, specifically the FDA's acceptance of the resubmitted new drug application for troriluzole.
Baird analyst Brian Skorney maintained a 'Buy' rating on Biohaven Ltd. (BHVN), indicating continued confidence in the company's long-term prospects. However, the price target was lowered from $52 to $48, suggesting a slight recalibration of near-term valuation expectations, likely due to the ongoing regulatory process for troriluzole. This event is a routine update in analyst coverage, providing a current perspective on the stock's valuation. For traders, the maintained 'Buy' rating offers some reassurance, but the reduced price target might temper immediate upside expectations, making it a neutral to slightly negative short-term signal for BHVN.